Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics

被引：32
作者：
Ballard, Peter
Bradbury, Robert H.
Harris, Craig S.
Hennequin, Laurent F. A.
Hickinson, Mark
Kettle, Jason G.
Kendrew, Jane
Klinowska, Teresa
Ogilvie, Donald J.
Pearson, Stuart E.
Williams, Emma J.
Wilson, Ingrid
机构：
[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
[2] AstraZeneca, Ctr Rech, F-51689 Reims 2, France
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 18期
关键词：
EGF; kinase; inhibitor; DMPK;
D O I：
10.1016/j.bmcl.2006.06.054
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The structure-activity and structure-property relationships of anilinoquinazoline inhibitors of EGFR were investigated. Strategies to lower volume of distribution and shorten half-life through structure and pK(a) modulation are discussed. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4908 / 4912
页数：5
相关论文
共 15 条
  • [1] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
    Barker, AJ
    Gibson, KH
    Grundy, W
    Godfrey, AA
    Barlow, JJ
    Healy, MP
    Woodburn, JR
    Ashton, SE
    Curry, BJ
    Scarlett, L
    Henthorn, L
    Richards, L
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1911 - 1914
  • [2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    Baselga, J
    Rischin, D
    Ranson, M
    Calvert, H
    Raymond, E
    Kieback, DG
    Kaye, SB
    Gianni, L
    Harris, A
    Bjork, T
    Averbuch, SD
    Feyereislova, A
    Swaisland, H
    Rojo, F
    Albanell, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
  • [3] United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets
    Cohen, MH
    Williams, GA
    Sridhara, R
    Chen, G
    McGuinn, WD
    Morse, D
    Abraham, S
    Rahman, A
    Liang, CY
    Lostritto, R
    Baird, A
    Pazdur, R
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (04) : 1212 - 1218
  • [4] Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
    Hennequin, LF
    Stokes, ESE
    Thomas, AP
    Johnstone, C
    Plé, PA
    Ogilvie, DJ
    Dukes, M
    Wedge, SR
    Kendrew, J
    Curwen, JO
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) : 1300 - 1312
  • [5] HENNEQUIN LFA, Patent No. 2003040109
  • [6] ZD6474 - clinical experience to date
    Heymach, JV
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (Suppl 1) : S14 - S20
  • [7] ERBB receptors and cancer: The complexity of targeted inhibitors
    Hynes, NE
    Lane, HA
    [J]. NATURE REVIEWS CANCER, 2005, 5 (05) : 341 - 354
  • [8] Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog
    McKillop, D
    Partridge, EA
    Hutchison, M
    Rhead, SA
    Parry, AC
    Bardsley, J
    Woodman, HM
    Swaisland, HC
    [J]. XENOBIOTICA, 2004, 34 (10) : 901 - 915
  • [9] A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
    Miller, KD
    Trigo, JM
    Wheeler, C
    Barge, A
    Rowbottom, J
    Sledge, G
    Baselga, J
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3369 - 3376
  • [10] MORTLOCK AA, Patent No. 2001021596
12